Business Standard

Sunday, December 22, 2024 | 10:40 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Niche players bet on bringing in therapies to India from abroad

Sundyota Numandis is bringing in global formulations in probiotics, nutraceuticals, hytopharmaceuticals through licensing route

graph
Premium

graph

Sohini Das Ahmedabad
Health care and pharma firms in niche therapies have sensed gains in bringing in drugs to India through deals with foreign companies and launching them under their brands.

Ahmedabad-based Sundyota Numandis Group has taken the licensing route to bring in products in probiotics, pharmabiotics, nutraceuticals, and phytopharmaceuticals (sourced from botanical extracts) from international firms.

Sundyota has also tied up with leading pharma players here such as Abbott India, Zydus Cadila, Alkem, Cipla, USV Pharma, Mankind Pharma, Ajanta Pharma, and Eris Lifesciences for manufacturing products that these players can launch under their brands.

Banking on these tie-ups, the firm is expecting to touch a

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in